{
    "Trade/Device Name(s)": [
        "FreeStyle Libre 2 Flash Glucose Monitoring System",
        "FreeStyle Libre 3 Continuous Glucose Monitoring System"
    ],
    "Submitter Information": "Abbott Diabetes Care, Inc.",
    "510(k) Number": "K223537",
    "Predicate Device Reference 510(k) Number(s)": [
        "K210943",
        "K213996",
        "K212132"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QLG",
        "NBW"
    ],
    "Summary Letter Date": "February 21, 2023",
    "Summary Letter Received Date": "November 23, 2022",
    "Submission Date": "November 21, 2022",
    "Regulation Number(s)": [
        "21 CFR 862.1355",
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Integrated Continuous Glucose Monitoring System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Interstitial fluid"
    ],
    "Specimen Container(s)": [
        "Sensor applicator",
        "Sensor pack"
    ],
    "Instrument(s)/Platform(s)": [
        "FreeStyle Libre 2 Sensor",
        "FreeStyle Libre 2 Reader",
        "FreeStyle Libre 2 App",
        "FreeStyle Libre 3 Sensor",
        "FreeStyle Libre 3 App"
    ],
    "Method(s)/Technology(ies)": [
        "Amperometric measurement",
        "Glucose oxidase chemical reaction",
        "Wireless data transmission (NFC, BLE)",
        "Cloud-based API (Libre Data Sharing API)"
    ],
    "Methodologies": [
        "Continuous glucose monitoring",
        "Factory calibrated sensor"
    ],
    "Submission Type(s)": [
        "System",
        "Sensor",
        "Reader",
        "App",
        "Software",
        "Accessory"
    ],
    "Document Summary": "FDA 510(k) summary for FreeStyle Libre 2 and FreeStyle Libre 3 continuous glucose monitoring systems with data sharing API for diabetes management",
    "Indications for Use Summary": "Indicated for management of diabetes in persons age 4 and older, replacing blood glucose testing for diabetes treatment decisions, detecting glucose trends and episodes, and autonomously communicating with digitally connected devices; not for use with automated insulin dosing systems.",
    "fda_folder": "Clinical Chemistry"
}